Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

Published:2014-07-21 Issue:10 Volume:89 Page:964-968
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Borthakur Gautam¹,Cortes Jorge E.¹,Estey Elihu E.²,Jabbour Elias¹,Faderl Stefan¹,O'Brien Susan¹,Garcia-Manero Guillermo¹,Kadia Tapan Mahendra¹,Wang Xuemei³,Patel Keyur⁴,Luthra Rajyalakshmi⁴,Koller Charles¹,Brandt Mark¹,Ravandi Farhad¹,Kantarjian Hagop¹

Affiliation:

1. Department of Leukemia; MD Anderson Cancer Center; Houston Texas

2. Division of Hematology; University of Washington School of Medicine; Seattle Washington

3. Department of Biostatistics; MD Anderson Cancer Center; Houston Texas

4. Department of Hematopathology; MD Anderson Cancer Center; Houston Texas

Funder

NIH/NCI

Publisher

Wiley

Subject

Hematology

Reference31 articles.

1. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered;Byrd;J Clin Oncol,1999

2. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461;Byrd;J Clin Oncol,2004

3. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study;Marcucci;J Clin Oncol,2005

4. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations;Appelbaum;Br J Haematol,2006

5. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML;Pollard;Blood,2010

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AML treatment: conventional chemotherapy and emerging novel agents;Trends in Pharmacological Sciences;2024-05

2. Allogeneic Stem Cell Transplantation in Refractory Acute Myeloid Leukaemia;Cells;2024-04-26

3. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia;Leukemia Research;2024-04

4. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study;Annals of Hematology;2024-01-26

5. Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms—A Systematic Review;Biomedicines;2024-01-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3